Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
News|Articles|October 2, 2025
Q3 2025: A recap of the top headlines and interviews
Fact checked by: Morgan Ebert, Executive Editor
View our Q3 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.
Advertisement
Advertisement
As we move into the fourth quarter of 2025, Q3 brought several treatment regulatory updates and clinical trial results to help better take care of pediatric patients across the globe.
Related to this article
Keisha L. Gibson, MD, MPH, discusses the FDA approval of Gazyva for childhood-onset INS and its implications for relapse prevention and pediatric care.
Hai D. Nguyen-Tran, MD, discusses clinical signs, neurologic warning symptoms, supportive care, and preventing the spread of hand, foot, and mouth disease.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
Children with FASD given choline before age 6 had 9.1% higher nonverbal IQ and 11.3% better working memory vs placebo 5 years after treatment.
A deep learning model reading 1 nondilated fundus photo predicted 1-year progression to high myopia in children with AUCs of 0.91-0.96.
Todd Wolynn, MD, MMM, FAAP, explains how pediatricians can address misinformation through empathetic communication and community engagement.
Advertisement
Advertisement